Study of a drug to prevent low white blood cells after immune-chemotherapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced small cell or non-small cell lung cancer, or advanced esophageal squamous cell cancer that cannot be cured with radical treatment.
- You have not had prior systemic anti-tumor treatment for your advanced cancer, or if you have had neoadjuvant/adjuvant treatment, at least 6 months have passed since your last chemotherapy before the cancer came back.
- You are about to receive at least 2 cycles of chemotherapy combined with immunotherapy that is known to increase the risk of low white blood cell count or fever from low counts.
- Your overall health and organ function must be adequate, as determined by blood tests and heart function.
- You must not have certain heart conditions, allergies to rubber or similar drugs, or have had bone marrow or stem cell transplants.
- You must not be pregnant or breastfeeding, and must not have other active cancers.
- You must not have used other investigational drugs within the past month or certain growth factors within the past 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
This trial tests a medication (Efbemalenograstim alfa) that helps boost your white blood cell counts during chemotherapy for ovarian or cervical cancer. It aims to reduce the risk of serious infections (febrile neutropenia) while you receive standard treatment with paclitaxel plus carboplatin or cisplatin, with or without bevacizumab.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.